JP2022505094A5 - - Google Patents

Info

Publication number
JP2022505094A5
JP2022505094A5 JP2021521000A JP2021521000A JP2022505094A5 JP 2022505094 A5 JP2022505094 A5 JP 2022505094A5 JP 2021521000 A JP2021521000 A JP 2021521000A JP 2021521000 A JP2021521000 A JP 2021521000A JP 2022505094 A5 JP2022505094 A5 JP 2022505094A5
Authority
JP
Japan
Prior art keywords
residue
complex
sequence
numbered
relation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021521000A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022505094A (ja
JP7584405B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2019/058777 external-priority patent/WO2020079586A1/en
Publication of JP2022505094A publication Critical patent/JP2022505094A/ja
Publication of JP2022505094A5 publication Critical patent/JP2022505094A5/ja
Application granted granted Critical
Publication of JP7584405B2 publication Critical patent/JP7584405B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021521000A 2018-10-17 2019-10-15 改変されたサイトメガロウイルスタンパク質及び安定化された複合体 Active JP7584405B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862746804P 2018-10-17 2018-10-17
US62/746,804 2018-10-17
PCT/IB2019/058777 WO2020079586A1 (en) 2018-10-17 2019-10-15 Modified cytomegalovirus proteins and stabilized complexes

Publications (3)

Publication Number Publication Date
JP2022505094A JP2022505094A (ja) 2022-01-14
JP2022505094A5 true JP2022505094A5 (cg-RX-API-DMAC7.html) 2022-10-31
JP7584405B2 JP7584405B2 (ja) 2024-11-15

Family

ID=68296588

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021521000A Active JP7584405B2 (ja) 2018-10-17 2019-10-15 改変されたサイトメガロウイルスタンパク質及び安定化された複合体

Country Status (8)

Country Link
US (2) US11932669B2 (cg-RX-API-DMAC7.html)
EP (1) EP3866845A1 (cg-RX-API-DMAC7.html)
JP (1) JP7584405B2 (cg-RX-API-DMAC7.html)
CN (1) CN113271968B (cg-RX-API-DMAC7.html)
BR (1) BR112021006812A2 (cg-RX-API-DMAC7.html)
CA (1) CA3116175A1 (cg-RX-API-DMAC7.html)
MX (1) MX2021004273A (cg-RX-API-DMAC7.html)
WO (1) WO2020079586A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021245611A1 (en) 2020-06-05 2021-12-09 Glaxosmithkline Biologicals Sa Modified betacoronavirus spike proteins
JP2023553854A (ja) 2020-12-02 2023-12-26 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ドナー鎖補完性fimh
US20250325656A1 (en) * 2022-05-20 2025-10-23 Glaxosmithkline Biologicals Sa Modified varicella zoster virus glycoprotein e proteins

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR920701453A (ko) 1989-03-17 1992-08-11 미리엄 디. 멕코나헤이 유전자발현의 외부조절
US5362865A (en) 1993-09-02 1994-11-08 Monsanto Company Enhanced expression in plants using non-translated leader sequences
US5693506A (en) 1993-11-16 1997-12-02 The Regents Of The University Of California Process for protein production in plants
WO2001000648A1 (en) 1999-06-25 2001-01-04 Progenics Pharmaceuticals, Inc. Stabilized viral envelope proteins and uses thereof
US7704510B2 (en) 2006-06-07 2010-04-27 The Trustees Of Princeton University Cytomegalovirus surface protein complex for use in vaccines and as a drug target
PE20141398A1 (es) 2008-07-16 2014-10-18 Inst Research In Biomedicine Anticuerpos neutralizantes de citomegalovirus humano
US8778359B2 (en) 2008-07-30 2014-07-15 Emergent Biosolutions Inc. Stable anthrax vaccine formulations
US9950062B2 (en) 2009-09-02 2018-04-24 Glaxosmithkline Biologicals Sa Compounds and compositions as TLR activity modulators
EP2659907A1 (en) 2012-05-01 2013-11-06 Affiris AG Compositions
AU2013286093B2 (en) 2012-07-06 2018-01-04 Novartis Ag Complexes of cytomegalovirus proteins
EP3269388A1 (en) 2012-10-30 2018-01-17 Pfizer Inc. Recombinant particle based vaccines against human cytomegalovirus infection
RS61993B1 (sr) * 2013-12-03 2021-07-30 Hookipa Biotech Gmbh Cmv vakcine
MX2016014660A (es) 2014-05-08 2017-02-28 Pfizer Medios y metodos para el tratamiento de cmv.
BE1023213B1 (fr) 2014-05-27 2016-12-21 Glaxosmithkline Biologicals Sa Complexes issus du cytomegalovirus et leurs utilisations
EP3048114A1 (en) 2015-01-22 2016-07-27 Novartis AG Cytomegalovirus antigens and uses thereof
EP3364981A4 (en) * 2015-10-22 2019-08-07 ModernaTX, Inc. VACCINE AGAINST THE HUMAN CYTOMEGALOVIRUS
US11833198B2 (en) 2017-03-28 2023-12-05 Children's Hospital Medical Center Norovirus S particle based vaccines and methods of making and using same

Similar Documents

Publication Publication Date Title
EP3319633B1 (en) Vaccine against rsv
PE20120358A1 (es) Mutantes fgf21 y usos de los mismos
FI3256579T3 (fi) Kysteiiniproteaasi
BRPI0412799A (pt) imunógeno, composição, ácido nucleico, célula recombinante, métodos para preparar um polipeptìdeo, para induzir um a resposta imune protetora em um paciente e para induzir uma resposta anamnésica em um paciente, e, seqüência de ácido nucleico otimizada de levedura
JP2018510622A5 (cg-RX-API-DMAC7.html)
FI3247722T3 (fi) Sytomegalovirusantigeenejä ja niiden käyttöjä
WO2010135491A3 (en) Fibroblast growth factor mutants having improved functional half-life and methods of their use
NZ603016A (en) Novel immunotherapy against several tumors including neuronal and brain tumors
MY150105A (en) A novel surface exposed haemophilus influenzae protein (protein e; pe)
EP4623996A3 (en) COMPOSITIONS AND METHODS FOR IDENTIFYING TUMOR-SPECIFIC NEOANTIGENS
CY1422A (en) Recombinant dna,hoats transformed with it and polypeptides produced by the hosts;processes for their preparation;detection processes using the polypeptides;compositions and means containing the polypeptides;dna sequences
JP2010504096A5 (cg-RX-API-DMAC7.html)
BRPI0411363A (pt) seqüências de ácidos nucléicos codificando e composições compreendendo peptìdeo sinal ige e/ou il-15 e processos para uso das mesmas
RU2020116307A (ru) Модифицированные белки vp1 норовируса и vlp, содержащие модифицированные белки vp1 норовируса
FI2956471T3 (fi) Il-1-beetan estäjän koostumus ja sen käyttö
JP2020518249A5 (cg-RX-API-DMAC7.html)
WO2021239838A3 (en) Severe acute respiratory syndrome coronavirus 2 (sars-cov-2) polypeptides and uses thereof for vaccine purposes
PE20020857A1 (es) Proteinas de fusion cuya parte del n-terminal es un derivado de hirudina para la produccion de proteinas recombinantes a traves de la secresion por levaduras
JP2010535504A5 (cg-RX-API-DMAC7.html)
BR112017022076A2 (pt) fusões de mesotelina-variante iii de receptor de fator de crescimento epidérmico e métodos de uso das mesmas
CN110746496A (zh) 一种鲍曼不动杆菌的pal重组蛋白及其编码基因和它们的应用
TW200716166A (en) Lawsonia intracellularis immunological proteins
RU2017104284A (ru) Выделенные полипептиды cd44 и их применение
JP2023510544A5 (cg-RX-API-DMAC7.html)
JP2015524420A5 (cg-RX-API-DMAC7.html)